NEW YORK (GenomeWeb News) – Transgenomic reported after the close of the market Tuesday that its first-quarter revenues fell 4 percent year over year due to a software problem that resulted in reduced sample processing capacity at its New Haven, Conn., lab testing facility.

The Omaha, Neb.-based firm had total revenues of $7.2 million for the three months ended March 31, compared to $7.5 million for the first quarter of 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.